Studies of anti–PD-1 antibody-based combinations in HL
| Drugs . | Phase . | Population . | N . | ORR, % . | CR, % . | DOR . | PFS . | Reference . |
|---|---|---|---|---|---|---|---|---|
| Nivolumab + AVD | 2 | Newly diagnosed | 51 | 84 | 67 | * | 94% at 9 mo (mPFS) | 40 |
| Nivolumab + BV | 1/2 | rel/ref (first salvage) | 61 | 82 | 61 | Not reached | 89% at 6 mo | 37 |
| Nivolumab + BV | 1 | rel/ref | 19 | 89 | 50 | * | 91% at 6 mo | 18 |
| Nivolumab + ipilimumab | 1 | rel/ref | 31 | 74 | 19 | Not reached | Not reached | 22 |
| Nivolumab or pembrolizumab + chemo (various) | Retrospective | rel/ref | 30 | * | 8.4 mo (median) | 36 | ||
| Anti–PD-1 + chemo | 11 | 90 | 45 | |||||
| Chemo after PD-1 | 19 | 61 | 32 |
| Drugs . | Phase . | Population . | N . | ORR, % . | CR, % . | DOR . | PFS . | Reference . |
|---|---|---|---|---|---|---|---|---|
| Nivolumab + AVD | 2 | Newly diagnosed | 51 | 84 | 67 | * | 94% at 9 mo (mPFS) | 40 |
| Nivolumab + BV | 1/2 | rel/ref (first salvage) | 61 | 82 | 61 | Not reached | 89% at 6 mo | 37 |
| Nivolumab + BV | 1 | rel/ref | 19 | 89 | 50 | * | 91% at 6 mo | 18 |
| Nivolumab + ipilimumab | 1 | rel/ref | 31 | 74 | 19 | Not reached | Not reached | 22 |
| Nivolumab or pembrolizumab + chemo (various) | Retrospective | rel/ref | 30 | * | 8.4 mo (median) | 36 | ||
| Anti–PD-1 + chemo | 11 | 90 | 45 | |||||
| Chemo after PD-1 | 19 | 61 | 32 |
chemo, chemotherapy; mPFS, modified progression-free survival.
Not reported.